tiprankstipranks
Trending News
More News >

Castle Biosciences to acquire Capsulomics, terms undisclosed

Castle Biosciences (CSTL) announced it has signed a definitive agreement to acquire Capsulomics, d/b/a Previse. Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases, including esophageal cancer. The terms of the agreement are undisclosed. The transaction is expected to close in the coming weeks, subject to the customary closing conditions.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue